SCHEMBL19544928

SCHEMBL19544928

COCCOc1ccc(Nc2ncnc(C)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.52
▸ BRAF P15056 1/20 0.51
▸ CDK4 P11802 1/20 0.51
▸ CCND1 P24385 1/20 0.51
▸ CCND2 P30279 1/20 0.51
▸ CCND3 P30281 1/20 0.51
▸ RAB9A P51151 2/20 0.44
▸ SYK P43405 2/20 0.43
▸ BTK Q06187 5/20 0.43
▸ EGFR P00533 4/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ LYN P07948 1/20 0.43
▸ TEC P42680 1/20 0.43
▸ TXK P42681 1/20 0.43
▸ BMX P51813 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ CD69 Q07108 1/20 0.43
▸ ITK Q08881 1/20 0.43
▸ HCK P08631 1/20 0.43
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1614114 0.86 KDM4E (0.54) MAPTBRAFCDK4CCND1CCND2
SCHEMBL19624911 0.83 BRAF (0.51) MAPTBRAFCDK4CCND1CCND2
SCHEMBL19754300 0.79 MAPT (0.54) MAPTBRAFCDK4CCND1CCND2
SCHEMBL19544927 0.78 SYK (0.57) MAPTBRAFCDK4CCND1CCND2
SCHEMBL19533535 0.76 BRAF (0.54) MAPTBRAFCDK4CCND1CCND2
SCHEMBL23409127 0.75 BRAF (0.53) BRAFCDK4CCND1CCND2CCND3
SCHEMBL29575809 0.75 BRAF (0.65) BRAFCDK4CCND1CCND2CCND3
SCHEMBL31688432 0.75 BRAF (0.52) BRAFCDK4CCND1CCND2CCND3
SCHEMBL17561055 0.74 KCNH3 (0.47) BRAFCDK4CCND1CCND2CCND3
SCHEMBL22909438 0.74 SYK (0.56) BRAFCDK4CCND1CCND2CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3246317-A1 BTK INHIBITOR Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) 2017-11-22 — — EP disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313683-A1 BTK INHIBITOR BTK, SYK, LYN MAPT 418/4885BRAF 110/4885CDK4 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback